⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

July 22, 2025

Supplementary Figure 4 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer

Rona Yaeger Riccardo Mezzadra Jenna Sinopoli Yu Bian Michelangelo Marasco Esther Kaplun Yijun Gao HuiYong Zhao Arnaud Da Cruz Paula Yingjie Zhu Almudena Chaves Perez Kalyani Chadalavada Edison Tse Sudhir Chowdhry Sydney Bowker Qing Chang Besnik Qeriqi Britta Weigelt Gouri J. Nanjangud Michael F. Berger Hirak Der‐Torossian Kenna Anderes Nicholas D. Socci Jinru Shia Gregory J. Riely Yonina R. Murciano‐Goroff Bob T. Li James G. Christensen Jorge S. Reis‐Filho David B. Solit Elisa de Stanchina Scott W. Lowe Neal Rosen Sandra Misale

View at Publisher

Ask AI

Bookmark

Share

Key Points

MAIN FINDING: Acquired resistance to KRAS G12C–EGFR inhibition was identified in colorectal cancer models.
KEY EVIDENCE: The study utilized patient-derived xenograft (PDX) models to explore resistance mechanisms.
APPROACH: The research generated specific PDX models to mimic acquired resistance in colorectal cancer.
SIGNIFICANCE: Understanding these mechanisms may guide future therapeutic strategies in targeting KRAS and EGFR.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Research demonstrates acquired resistance mechanisms in colorectal cancer models, implying potential therapeutic challenges.

Abstract

Generation of acquired resistance PDX model

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Yaeger et al. (2025) studied this question.

synapsesocial.com/papers/689a061be6551bb0af8cd933 https://doi.org/10.1158/2159-8290.29619027

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure 1 from Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal Cancer2025
2Supplementary Figure 5 from Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal Cancer2025
3Supplementary Figure 2 from Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal Cancer2025
4Supplementary Figure 6 from Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal Cancer2025
5Supplemental Figure S6 from D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities2024